Literature DB >> 27800239

Comparison of Pattern Electroretinography and Optical Coherence Tomography Parameters in Patients with Primary Open-Angle Glaucoma and Ocular Hypertension.

Semra Tiryaki Demir1, Mehmet Ersin Oba2, Ezgi Tuna Erdoğan3, Mahmut Odabaşı4, Ayşe Burcu Dirim1, Mehmet Demir1, Efe Can1, Orhan Kara1, Selam Yekta Şendül1.   

Abstract

OBJECTIVES: To investigate the correlation of visual field (VF), pattern electroretinography (PERG) and Fourier domain optical coherence tomography (FD-OCT) results in patients with ocular hypertension (OHT) and early primary open-angle glaucoma (POAG).
MATERIALS AND METHODS: The study included 72 eyes of 37 patients with early POAG, 76 eyes of 38 patients with OHT, and 60 eyes of 30 controls. All subjects underwent full ophthalmologic examination, VF assessment with 24-2 Humphrey standard automated perimetry (Swedish Interactive Thresholding Algorithm (SITA)-Standard), retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thickness measurement with FD-OCT, and PERG P50 and N95 wave latency and amplitude measurements with electroretinography (Nihon Kohden).
RESULTS: With the exception of the nasal quadrant, all GCC parameters and RNFL results were significantly lower in the POAG group compared to the OHT and control groups. There was no statistically significant difference between the OHT and control group. PERG amplitudes were lower in the POAG and OHT groups than in the control group. Reduction in N95 amplitude was greater than that of P50 amplitude. No difference was detected in PERG latencies among groups. GCC was significantly correlated with VF and RNFL in the POAG group.
CONCLUSION: Significant thinning of the GCC and RNFL occurs in addition to VF pathologies in patients with early POAG, and these examinations should be concomitantly evaluated. During diagnostic assessment of patients with early POAG, GCC and RNFL analysis by FD-OCT are highly effective. GCC is as reliable as RNLF in the early diagnosis of glaucoma and there is a highly significant correlation between them. Dysfunction of ganglion cells in patients with OHT may be detected earlier using PERG amplitude analysis.

Entities:  

Keywords:  Retinal nerve fiber layer; ganglion cell complex; ocular hypertension; pattern electroretinogram; primary open-angle glaucoma

Year:  2015        PMID: 27800239      PMCID: PMC5082259          DOI: 10.4274/tjo.39260

Source DB:  PubMed          Journal:  Turk J Ophthalmol        ISSN: 2149-8709


  33 in total

1.  Retinal nerve fiber layer thickness reproducibility using seven different OCT instruments.

Authors:  Luisa Pierro; Marco Gagliardi; Lorenzo Iuliano; Alessandro Ambrosi; Francesco Bandello
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-31       Impact factor: 4.799

2.  Comparative study of macular ganglion cell complex thickness measured by spectral-domain optical coherence tomography in healthy eyes, eyes with preperimetric glaucoma, and eyes with early glaucoma.

Authors:  Yu Jeong Kim; Min Ho Kang; Hee Yoon Cho; Han Woong Lim; Mincheol Seong
Journal:  Jpn J Ophthalmol       Date:  2014-03-11       Impact factor: 2.447

Review 3.  Pattern electroretinography (PERG) and an integrated approach to visual pathway diagnosis.

Authors:  G E Holder
Journal:  Prog Retin Eye Res       Date:  2001-07       Impact factor: 21.198

4.  Visual field defects and retinal ganglion cell losses in patients with glaucoma.

Authors:  Ronald S Harwerth; Harry A Quigley
Journal:  Arch Ophthalmol       Date:  2006-06

5.  Glaucomatous eye macular ganglion cell complex thickness and its relation to temporal circumpapillary retinal nerve fiber layer thickness.

Authors:  Yoshiyuki Kita; Ritsuko Kita; Ai Nitta; Chiaki Nishimura; Goji Tomita
Journal:  Jpn J Ophthalmol       Date:  2011-05-03       Impact factor: 2.447

6.  A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.

Authors:  Paul P Lee; John G Walt; John J Doyle; Sameer V Kotak; Stacy J Evans; Donald L Budenz; Philip P Chen; Anne L Coleman; Robert M Feldman; Henry D Jampel; L Jay Katz; Richard P Mills; Jonathan S Myers; Robert J Noecker; Jody R Piltz-Seymour; Robert R Ritch; Paul N Schacknow; Janet B Serle; Gary L Trick
Journal:  Arch Ophthalmol       Date:  2006-01

7.  Incidence and prevalence of short wavelength automated perimetry deficits in ocular hypertensive patients.

Authors:  S Demirel; C A Johnson
Journal:  Am J Ophthalmol       Date:  2001-06       Impact factor: 5.258

8.  Structure-function relationship in ocular hypertension and glaucoma: interindividual and interocular analysis by OCT and pattern ERG.

Authors:  Benedetto Falsini; Dario Marangoni; Tommaso Salgarello; Giovanna Stifano; Lucrezia Montrone; Francesca Campagna; Stefania Aliberti; Emilio Balestrazzi; Alberto Colotto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-02       Impact factor: 3.117

Review 9.  Update on the pattern electroretinogram in glaucoma.

Authors:  Michael Bach; Michael B Hoffmann
Journal:  Optom Vis Sci       Date:  2008-06       Impact factor: 1.973

10.  Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography.

Authors:  Ou Tan; Vikas Chopra; Ake Tzu-Hui Lu; Joel S Schuman; Hiroshi Ishikawa; Gadi Wollstein; Rohit Varma; David Huang
Journal:  Ophthalmology       Date:  2009-09-10       Impact factor: 12.079

View more
  2 in total

1.  Analysis of pattern electroretinogram signals of early primary open-angle glaucoma in discrete wavelet transform coefficients domain.

Authors:  Homa Hassankarimi; Seyed Mohammad Reza Noori; Ebrahim Jafarzadehpour; Shahin Yazdani; Fatemeh Radinmehr
Journal:  Int Ophthalmol       Date:  2019-02-06       Impact factor: 2.031

2.  Can We Corroborate Peripapillary RNFL Analysis with Macular GCIPL Analysis? Our 2-Year Experience at a Single-Centre Tertiary Healthcare Hospital Using Two OCT Machines and a Review of Literature.

Authors:  Sangeeta Abrol; Sukriti Gupta; Mayuresh Naik; Siddharth Agarwal
Journal:  Clin Ophthalmol       Date:  2020-11-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.